Multiple sclerosis trial designs for the 21st century: Building on recent lessons

Journal of Neurology

Volumn 252, Issue SUPPL. 5, 2005, Pages

  Lublin, Fred ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Drug development; Multiple sclerosis; Treatment

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; GADOLINIUM; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON; INTERFERON BETA SERINE; MITOXANTRONE; MYELIN; NATALIZUMAB; NEUROPROTECTIVE AGENT; ROQUINIMEX; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CROHN DISEASE; DISABILITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; LOW DRUG DOSE; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; SCORING SYSTEM; VALIDATION PROCESS;

CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN;

EID: 27444443629     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-5008-1     Document Type: Conference Paper

References (32)

1. Bornstein MB, Miller A, Slagle S, et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317:408-414
2. Brex PA, Ciccarelli O, O'Riordan JI, et al. (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158-164
3. Cohen JA, Cutter GR, Fischer JS, et al. (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59:679-687
4. Comi G, Filippi M, Wolinsky JS, et al. (2001) The European/Canadian multicenter, double-blind, randomised placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing and remitting multiple sclerosis. Ann Neurol 49:290-297
5. Cutter GR, Baier ML, Rudick RA, et al. (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122:871-882
6. European Study Group on Interferon β-1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
7. Filippi M, Rovaris M, Rocca MA, et al. (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 57:731-733
8. Ford C, Johnson K, Brooks B, et al. (2003) Sustained efficacy and tolerability of glatiramer acetate in relapsing-remitting multiple sclerosis patients for over ten years. Multiple Sclerosis 9(Suppl 1):S120
9. Jacobs LD, Cookfair DL, Rudick RA, et al. (1996) Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
10. Johnson KP, Brooks BR, Cohen JA, et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45:1268-1276
11. Johnson KP, Brooks BR, Ford CC, et al. (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 6:255-266
12. Kappos L, Moeri D, Radue EW, et al. (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 353:964-969
13. Kurtzke JF (1983) Rating neurological impairment in MS: an expanded disability status scale (EDSS). Neurology 33:1444-1452
14. Lublin FD, Baier M, Cutter G (2003) Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61:1528-1532
15. Lublin FD, Cutter G, Elfont R, et al. (2001) A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing-remitting MS. Neurology 56(Suppl):S20.002
16. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-911
17. Mainero C, De Stefano N, Iannucci G, et al. (2001) Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 56:1331-1334
18. McDonald WI, Compston A, Edan G, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
19. Noseworthy JH, O'Brien P, Erickson BJ, et al. (1998) The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 51:1342-1352
20. O'Riordan JI, Thompson AJ, Kingsley DP, et al. (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNSA 10-year follow-up. Brain 121:495-503
21. Panitch H, Goodin DS, Francis G, et al. (2002) Evidence of Interferon Dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496-1506
22. Panitch H, Miller A, Paty D, Weinshenker B (2004) North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63:1788-1795
23. Polman C, O'Connor P, Havrdova E, et al. (2005) Clinical results from AFFIRM: a randomised, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing-remitting multiple sclerosis (MS). Neurology 64(Suppl 1):S16.003
24. Poser CM, Paty DW, Scheinberg I, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
25. Rovaris M, Agosta F, Sormani MP, et al. (2003) Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 126:2323-2332
26. Rudick R, Stuart W, Calabresi P, et al. (2005) SENTINEL: a randomised, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab when added to intramuscular interferon-β1a in patients with relapsing-remitting multiple sclerosis (MS). One year clinical and MRI results. Neurology 64(Suppl 1):S36.001
27. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1β in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
28. The PRISMS STUDY GROUP and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628-1636
29. van Waesberghe JH, Kamphorst W, de Groot CJ, et al. (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747-754
30. van Walderveen MAA, Barkhof F, Hommes OR, et al. (1995) Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/short TE (T1-weighted) spin-echo images. Neurology 45:1684-1690
31. Weinshenker BG, Bass B, Rice GP, et al. (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112:1419-1428
32. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC (1991) The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 114:1045-1056